{"nctId":"NCT00329433","briefTitle":"Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery","startDateStruct":{"date":"2006-05"},"conditions":["Deep Venous Thrombosis"],"count":120,"armGroups":[{"label":"Heparin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Heparin"]},{"label":"Desirudin (Iprivask™)","type":"EXPERIMENTAL","interventionNames":["Drug: Desirudin (Iprivask™)"]}],"interventions":[{"name":"Desirudin (Iprivask™)","otherNames":[]},{"name":"Heparin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who are scheduled for elective Cardiac or Thoracic Surgery.\n* Age \\> 18 years of age.\n\nExclusion Criteria:\n\n* Patients with a clinical suspicion or a documented history of DVT/PE\n* Patients who may require anticoagulation during the post-op period. (i.e. Patients with a history of A-fib, scheduled for a MAZE procedure or placement of a mechanical valve, or those on Coumadin/IV heparin preoperatively)\n* Patients who have a history of HIT or if there is a suspicion of the patient having HIT pre-operatively.\n* Documented allergy to heparin, desirudin, or lepirudin\n* Patients with a history of coagulation disorder\n* Platelet count\\< 100 X109 /dl\n* Active bleeding\n* Serum Creatinine ≥ 1.5 mg/dl or CrCl ≤ 30 ml/min\n* Patients with a baseline coagulopathy (INR \\> 1.5 or aPTT \\> 45 sec)\n* Patients with liver disease\n* Pregnancy\n* Patients who require ventricular assist devices before or after surgery","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Primary Outcome Measure Was the Number of Participants With New Heparin Platelet Factor 4 (HIT Positive) Antibodies in Each Group Within 30 Days Following Surgery.","description":"Blood samples were collected and tested in singlet for the presence of PF4/heparin antibodies. Samples were collected for each participant on PDD (Post-study Drug initiation Day) 2, PDD 7 or at hospital discharge, and at 30 days post surgery.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"The Incidence of DVTs in Each Group.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"The Incidence of Bleeding in Each Group.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":61},"commonTop":[]}}}